Postmenopausal osteoporosis treatment with antiresorptives: Effects of discontinuation or long-term continuation on bone turnover and fracture risk-a perspective

Adverse Reactions and Drug–Drug Interactions in the Management of Women with Postmenopausal Osteoporosis

(2011) René Rizzoli et al.   CALCIFIED TISSUE INTERNATIONAL

Health Outcomes After Stopping Conjugated Equine Estrogens Among Postmenopausal Women With Prior Hysterectomy

(2011) Andrea Z. LaCroix   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)

(2011) Dennis M Black et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Osteoporosis Medication and Reduced Mortality Risk in Elderly Women and Men

(2011) Jacqueline R. Center et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Effects of Denosumab Treatment and Discontinuation on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Women with Low Bone Mass

(2011) Henry G. Bone et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma

(2011) David H. Henry et al.   JOURNAL OF CLINICAL ONCOLOGY

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

(2011) Karim Fizazi et al.   LANCET

Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study

(2011) S. L. Silverman et al.   OSTEOPOROSIS INTERNATIONAL

Biomechanical computed tomography-noninvasive bone strength analysis using clinical computed tomography scans

(2010) Tony M. Keaveny   Annals of the New York Academy of Sciences

Denosumab and bisphosphonates: Different mechanisms of action and effects

(2010) Roland Baron et al.   BONE

Increases in Hip and Spine Bone Mineral Density are Predictive for Vertebral Antifracture Efficacy with Ibandronate

(2010) Paul D. Miller et al.   CALCIFIED TISSUE INTERNATIONAL

Adverse Effects of Bisphosphonates

(2010) Bo Abrahamsen   CALCIFIED TISSUE INTERNATIONAL

Markers of bone resorption predict hip fracture in elderly women: The EPIDOS prospective study

(2010) P. Garnero et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Prolonged antiresorptive activity of zoledronate: A randomized, controlled trial

(2010) Andrew Grey et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Microarchitectural deterioration of cortical and trabecular bone: Differing effects of denosumab and alendronate

(2010) Ego Seeman et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: The FLEX Trial

(2010) Ann V Schwartz et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Effects of denosumab on bone histomorphometry: The FREEDOM and STAND studies

(2010) Ian R Reid et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Odanacatib in the treatment of postmenopausal women with low bone mineral density: Three-year continued therapy and resolution of effect

(2010) John A Eisman et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Long-Term Use of Bisphosphonates in Osteoporosis

(2010) Nelson B. Watts et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Effect of Denosumab on Bone Mineral Density and Biochemical Markers of Bone Turnover: Six-Year Results of a Phase 2 Clinical Trial

(2010) Paul D. Miller et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Bone turnover markers and prediction of fracture: A prospective follow-up study of 1040 elderly women for a mean of 9 years

(2009) Kaisa K Ivaska et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Risedronate reduces intracortical porosity in women with osteoporosis

(2009) Babul Borah et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis

(2009) Steven R. Cummings et al.   NEW ENGLAND JOURNAL OF MEDICINE

Zoledronic Acid for the Prevention of Bone Loss in Postmenopausal Women With Low Bone Mass

(2009) Michael McClung et al.   OBSTETRICS AND GYNECOLOGY

Bone turnover markers: understanding their value in clinical trials and clinical practice

(2009) R. Civitelli et al.   OSTEOPOROSIS INTERNATIONAL

How can bone turnover modify bone strength independent of bone mass?

(2008) C.J. Hernandez   BONE

Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial

(2008) Paul D. Miller et al.   BONE

Health Risks and Benefits 3 Years After Stopping Randomized Treatment With Estrogen and Progestin

(2008) Gerardo Heiss   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Optimal Thresholds, Linear or Nonlinear Relationships of Fracture Risk Reduction With Therapy

(2008) Douglas C Bauer et al.   JOURNAL OF BONE AND MINERAL RESEARCH

The Antiresorptive Effects of a Single Dose of Zoledronate Persist for Two Years: A Randomized, Placebo-Controlled Trial in Osteopenic Postmenopausal Women

(2008) Andrew Grey et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy

(2008) R. G. G. Russell et al.   OSTEOPOROSIS INTERNATIONAL

Osteonecrosis of the Jaw in Patients Receiving Intravenous or Oral Bisphosphonates

(2008) Amber E King et al.   PHARMACOTHERAPY

Biomarkers of bone health and osteoporosis risk

(2008) Richard Eastell et al.   PROCEEDINGS OF THE NUTRITION SOCIETY

Effect of Raloxifene on Stroke and Venous Thromboembolism According to Subgroups in Postmenopausal Women at Increased Risk of Coronary Heart Disease

(2008) Lori Mosca et al.   STROKE